title: Biosimilar Medicines Group - 14th Annual Medicines for Europe Conference (April 28-29, 2016 - London, UK).
abstract: Biotechnology has enabled the development of treatments for many diseases benefiting millions of people. Similar biologics or 'biosimilar' versions of originator biologic medicines are a relatively new category of biologics, usually developed when the originator is protected by patent exclusivity and introduced to healthcare systems as a cheaper option to treat disease. Biosimilars provide value and thus access for new groups of patients because they bring cost savings to the healthcare ecosystem. Generics achieved cost savings of EUR 100 billion in 2014, which allows the system to finance more innovative methods of bringing medicines to patients. The Medicines for Europe Biosimilars Medicines Group Conference in London is the main annual biosimilars gathering and attracts the world's experts. A recurring theme throughout this year's conference was the promotion of a multi-stakeholder approach; if stakeholders work together they will collectively give patients more opportunity to benefit from biologic medicines. In discussion were the latest developments in the biosimilars market, including the ongoing challenges against adoption of biosimilars.
authors.affiliation: Thomson Reuters, London, UK. lisa.hodgkinson@thomsonreuters.com.
authors.forename: L
authors.initials: L
authors.lastname: Hodgkinson
keywords: Biosimilars; CT-P13; Filgrastim; Infliximab; Omnitrope